Amantadine-induced syndrome of inappropriate antidiuretic hormone secretion
10.3760/cma.j.cn114015-20211230-01314
- VernacularTitle:金刚烷胺致抗利尿激素分泌异常综合征
- Author:
Xiaoli YAO
1
;
Weizhong XIAO
Author Information
1. 郑州大学附属郑州中心医院神经内科，郑州 450007
- Publication Type:Journal Article
- Keywords:
Parkinson disease;
Amantadine;
Inappropriate ADH syndrome
- From:
Adverse Drug Reactions Journal
2022;24(8):444-446
- CountryChina
- Language:Chinese
-
Abstract:
A 64-year-old male patient with Parkinson′s disease received long-term use of levodopa and benserazide hydrochloride, piribedil sustained-release tablets, and selegiline. Due to involuntary twisting of head and limbs, amantadine was added and dyskinesia was relieved. Five months later, the patient felt general fatigue and weakness, and the blood sodium was 120 mmol/L. He was given sodium supplementation treatment, and the blood sodium level rose briefly and then decreased again. Excluding other factors that could cause hyponatremia, it was considered that the hyponatremia was caused by syndrome of inappropriate antidiuretic hormone secretion, which was induced by amantadine. Amantadine was stopped, sodium supplement treatment was continued, and 7 days later, the blood sodium level gradually returned to normal. After stopping sodium supplementation, fatigue and weakness did not recur, and blood sodium level did not decrease at one month of follow-up.
